Atara Biotherapeutics
Mar 9, 2017

Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial results for the fourth quarter and full year ended December 31, 2016 and recent operational highlights.

"We believe 2017 will be a transformative year for Atara Bio as we continue to advance our robust pipeline of allogeneic T-cell therapies to address multiple diseases with high unmet medical need," said Isaac Ciechanover, Chief Executive Officer and President of Atara Bio. "In December of last year, we reached agreement with the FDA on the designs of two separate Phase 3 trials of ATA129 in the treatment of EBV-PTLD, and more recently we announced EMA support for our plan to submit a conditional marketing authorization application for potential approval of ATA129 in the EU."

Recent Highlights and Anticipated Upcoming Milestones

Fourth Quarter and Full Year 2016 Financial Results

About Atara Biotherapeutics' Allogeneic Cellular Therapy Platform

Atara Bio's cellular therapy platform provides healthy immune capability to a patient and arms the immune system to precisely target and combat disease. Cells derived from healthy donors are manufactured in advance and stored as inventory so that a customized unit of cells can be chosen for each patient. The cells are ready to infuse in approximately 3 to 5 days. Once administered, the cells home to their target, expand in-vivo to eliminate diseased cells, and eventually recede. This versatile platform can be directed towards a broad array of disease causing targets and has demonstrated clinical proof of concept across both viral and non-viral targets in conditions ranging from liquid and solid tumors to infectious and autoimmune diseases. The Company has pursued prospective feedback from health authorities on both manufacturing and clinical trial design. Atara Bio's lead product candidate has the potential to be the first commercial allogeneic T-cell therapy for a viral target implicated in cancer.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on allogeneic T-cell therapies for cancer, autoimmune, and infectious disease. Atara Bio's T-cell product candidates harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The Company's initial clinical stage T-cell product candidates include Epstein-Barr virus targeted Cytotoxic T-cells (EBV-CTL), or ATA129, Cytomegalovirus targeted Cytotoxic T-cells (CMV-CTL), or ATA230, and Wilms Tumor 1 targeted Cytotoxic T-cells (WT1-CTL), or ATA520. These product candidates have demonstrated the potential to have therapeutic benefit in a number of clinical indications including hematologic malignancies, solid tumors, and refractory viral infections. The Company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cell's ability to target specific viral proteins implicated in disease. Initial clinical investigations employing this approach will focus on multiple sclerosis and other virally mediated cancers and infections.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the Company's belief that 2017 will be a transformative year for Atara Bio; the Company's plan to submit a conditional marketing authorization application for potential approval of ATA129 in the EU; the Company's belief that it has been successful in producing ATA129 drug product; the Company's refinement of certain assays, manufacture of lots to further support comparability evaluations and the Phase 3 trials, and expectations to review these data with FDA prior to starting these trials; plans for the CMA to be based on clinical data from Phase 1 and 2 trials conducted at MSK and supported by available data from the Company's Phase 3 MATCH and ALLELE trials, which will be ongoing at the time of filing; the Company's expectation that its collaborating investigators will present at a medical conference in 2017 initial data from a Phase 1 trial of the autologous version of ATA188 in patients with primary and secondary progressive MS; the Company's plan to initiate a Phase 1 trial of ATA188 in MS in the second half of 2017; the Company's plan to build-out a multi-product cellular therapy manufacturing facility with manufacturing operations expected to commence in 2018; and the Company's belief that its cash and investments as of December 31, 2016 will be sufficient to fund its planned operations into the first quarter of 2019. Because such statements deal with future events and are based on Atara Bio's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Bio could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those discussed under the heading "Risk Factors" in Atara Bio's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 4, 2016, including the documents incorporated by reference therein, and subsequent filings with the SEC. Except as otherwise required by law, Atara Bio disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Atara Biotherapeutics, Inc.  
Consolidated Balance Sheets 
(In thousands) 
  December 31,  December 31, 
  2016  2015 
Current assets:        
Cash and cash equivalents $47,968  $23,746 
Short-term investments  207,714   296,736 
Restricted cash  194   194 
Prepaid expenses and other current assets  4,677   3,921 
Total current assets  260,553   324,597 
Property and equipment, net  3,259   270 
Other assets  102   108 
Total assets $263,914  $324,975 
Liabilities and stockholders' equity        
Current liabilities:        
Accounts payable $2,778  $1,445 
Accrued compensation  3,745   2,624 
Accrued research and development expenses  2,408   5,112 
Other accrued liabilities  744   528 
Total current liabilities  9,675   9,709 
Long-term liabilities  503   166 
Total liabilities  10,178   9,875 
Commitments and contingencies         
Stockholders' equity:        
Common stock  3   3 
Additional paid-in capital  431,075   413,725 
Accumulated other comprehensive loss  (183)  (518)
Accumulated deficit  (177,159)  (98,110)
Total stockholders' equity  253,736   315,100 
Total liabilities and stockholders' equity $263,914  $324,975 


Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
 Three Months Ended
December 31,
 Year Ended
December 31,
  2016   2015   2016   2015 
Operating expenses:       
Research and development$13,474  $16,231  $56,514  $41,618 
General and administrative 5,280   5,539   24,728   16,830 
Total operating expenses 18,754   21,770   81,242   58,448 
Loss from operations (18,754)  (21,770)  (81,242)  (58,448)
Interest and other income, net 519   522   2,203   1,218 
Loss before provision for income taxes (18,235)  (21,248)  (79,039)  (57,230)
Provision (benefit) for income taxes -   -   10   (9)
Net loss$(18,235) $(21,248) $(79,049) $(57,221)
Other comprehensive loss:       
Unrealized gain (loss) on available-for-sale securities (218)  (569)  335   (418)
Comprehensive loss$(18,453) $(21,817) $(78,714) $(57,639)
Net loss per common share:       
Basic and diluted net loss per common share:$(0.63) $(0.75) $(2.75) $(2.24)
Weighted-average common shares outstanding used to
  calculate basic and diluted net loss per common share
 28,915   28,413   28,732   25,583 



Steve Klass, Burns McClellan on behalf of Atara Bio
212-213-0006 x331

Justin Jackson, Burns McClellan
212-213-0006 x327